Symbols / GRTX $0.10 +0.00% Galera Therapeutics, Inc.
GRTX Chart
Stock Fundamentals
|
|
|
|
|
|
About
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC). The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Ratings
Current target
$0.10
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-08-29 | main | Citigroup | Neutral → Neutral | $0 |
| 2023-08-16 | down | HC Wainwright & Co. | Buy → Neutral | $0 |
| 2023-08-10 | down | Piper Sandler | Overweight → Neutral | $1 |
| 2023-07-17 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-03-22 | main | HC Wainwright & Co. | — → Buy | $6 |
| 2023-02-21 | init | Piper Sandler | — → Overweight | $6 |
| 2023-02-16 | up | B of A Securities | Underperform → Buy | $7 |
| 2023-02-16 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2022-05-27 | down | B of A Securities | Neutral → Underperform | $2 |
| 2021-12-20 | main | Citigroup | — → Buy | $20 |
| 2021-12-15 | up | HC Wainwright & Co. | Neutral → Buy | $10 |
| 2021-12-15 | up | BTIG | Neutral → Buy | $15 |
| 2021-10-20 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2021-10-19 | down | BTIG | Buy → Neutral | — |
| 2020-12-16 | up | Credit Suisse | Neutral → Outperform | $15 |
| 2020-12-07 | init | HC Wainwright & Co. | — → Buy | $15 |
| 2020-11-11 | main | Credit Suisse | — → Neutral | $9 |
| 2020-07-29 | main | Credit Suisse | — → Neutral | $8 |
| 2019-12-02 | init | BTIG | — → Buy | $30 |
| 2019-12-02 | init | B of A Securities | — → Buy | $15 |
- GRTX SEC Filings - Galera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan ue, 12 May 2026 13
- GRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire ue, 14 Apr 2026 07
- Galera Therapeutics (OTCQB: GRTX) holders approve share boost and reverse split - Stock Titan Mon, 11 May 2026 20
- Galera Shareholders Approve Governance Changes and Share Increase - TipRanks Mon, 11 May 2026 21
- GRTX | GALERA THERAPEUTICS INC Insider Trading - Quiver Quantitative ue, 14 Apr 2026 18
- Halper Sadeh LLC is Investigating Whether LEG, AVNS, SEM, GRTX are Obtaining Fair Deals for their Shareholders - Scott Coop hu, 23 Apr 2026 02
- Galera Announces Obsidian Merger and $350M Financing - The Globe and Mail Wed, 15 Apr 2026 07
- Galera Therapeutics (GRTX) to Merge with Obsidian Therapeutics - GuruFocus ue, 14 Apr 2026 07
- Emerald Bioventures details major Galera Therapeutics (GRTX) equity stake - Stock Titan Mon, 04 May 2026 21
- Galera Therapeutics Announces Share Conversions and Warrant Exercise - TipRanks hu, 09 Apr 2026 07
- Emerald backs Galera–Obsidian deal with 26.5% Galera (GRTX) stake - Stock Titan Mon, 27 Apr 2026 07
- Obsidian–Galera (OTC: GRTX) merger adds $350M PIPE to fund OBX-115 - Stock Titan ue, 14 Apr 2026 07
- Galera Therapeutics (NASDAQ: GRTX) to merge with Obsidian; S-4 and proxy planned - Stock Titan Wed, 22 Apr 2026 07
- Director grows Galera (NASDAQ: GRTX) stake via private placement and merger - Stock Titan Fri, 10 Apr 2026 07
- Preferred conversion and warrant exercise reshape Galera (GRTX) common stock - Stock Titan hu, 09 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
6.04
-57.31%
|
14.15
-69.86%
|
46.95
-8.35%
|
51.23
|
| Research And Development |
|
0.35
-88.92%
|
3.15
-86.93%
|
24.11
-22.24%
|
31.01
|
| Selling General And Administration |
|
5.69
-48.25%
|
11.00
-51.82%
|
22.84
+12.97%
|
20.21
|
| General And Administrative Expense |
|
5.69
-48.25%
|
11.00
-51.82%
|
22.84
+12.97%
|
20.21
|
| Other Gand A |
|
5.69
-48.25%
|
11.00
-51.82%
|
22.84
+12.97%
|
20.21
|
| Total Expenses |
|
6.04
-57.31%
|
14.15
-69.86%
|
46.95
-8.35%
|
51.23
|
| Operating Income |
|
-6.04
+57.31%
|
-14.15
+69.86%
|
-46.95
+8.35%
|
-51.23
|
| Total Operating Income As Reported |
|
-2.54
+87.39%
|
-20.16
+59.07%
|
-49.26
+3.84%
|
-51.23
|
| EBITDA |
|
-6.04
+57.25%
|
-14.13
+70.19%
|
-47.41
+6.32%
|
-50.61
|
| Normalized EBITDA |
|
-160.88
-1776.87%
|
-8.57
+80.99%
|
-45.10
+10.89%
|
-50.61
|
| Reconciled Depreciation |
|
0.00
-100.00%
|
0.02
-92.28%
|
0.26
+127.19%
|
0.11
|
| EBIT |
|
-6.04
+57.31%
|
-14.15
+70.31%
|
-47.67
+6.02%
|
-50.72
|
| Total Unusual Items |
|
154.84
+2884.45%
|
-5.56
-140.53%
|
-2.31
-231100.00%
|
-0.00
|
| Total Unusual Items Excluding Goodwill |
|
154.84
+2884.45%
|
-5.56
-140.53%
|
-2.31
-231100.00%
|
-0.00
|
| Special Income Charges |
|
154.55
+2672.82%
|
-6.01
-160.16%
|
-2.31
|
0.00
|
| Other Special Charges |
|
-151.05
-5366.70%
|
2.87
|
—
|
—
|
| Impairment Of Capital Assets |
|
0.00
-100.00%
|
3.14
|
0.00
|
—
|
| Restructuring And Mergern Acquisition |
|
—
|
0.00
-100.00%
|
2.31
|
0.00
|
| Net Income |
|
149.05
+886.25%
|
-18.96
+67.91%
|
-59.08
+5.05%
|
-62.22
|
| Pretax Income |
|
149.05
+877.92%
|
-19.16
+67.57%
|
-59.08
+5.15%
|
-62.29
|
| Net Non Operating Interest Income Expense |
|
0.25
-55.23%
|
0.55
+105.64%
|
-9.82
+11.26%
|
-11.06
|
| Interest Expense Non Operating |
|
—
|
0.00
-100.00%
|
11.41
-1.36%
|
11.57
|
| Net Interest Income |
|
0.25
-55.23%
|
0.55
+105.64%
|
-9.82
+11.26%
|
-11.06
|
| Interest Expense |
|
—
|
0.00
-100.00%
|
11.41
-1.36%
|
11.57
|
| Interest Income Non Operating |
|
0.25
-55.23%
|
0.55
-65.27%
|
1.59
+215.22%
|
0.51
|
| Interest Income |
|
0.25
-55.23%
|
0.55
-65.27%
|
1.59
+215.22%
|
0.51
|
| Other Income Expense |
|
154.84
+2884.45%
|
-5.56
-140.53%
|
-2.31
-231100.00%
|
-0.00
|
| Gain On Sale Of Security |
|
0.29
-34.08%
|
0.45
+14966.67%
|
-0.00
-200.00%
|
-0.00
|
| Tax Provision |
|
0.00
+100.00%
|
-0.20
|
0.00
+100.00%
|
-0.07
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-0.06
|
0.00
+100.00%
|
-0.00
|
| Net Income Including Noncontrolling Interests |
|
149.05
+886.25%
|
-18.96
+67.91%
|
-59.08
+5.05%
|
-62.22
|
| Net Income From Continuing Operation Net Minority Interest |
|
149.05
+886.25%
|
-18.96
+67.91%
|
-59.08
+5.05%
|
-62.22
|
| Net Income From Continuing And Discontinued Operation |
|
149.05
+886.25%
|
-18.96
+67.91%
|
-59.08
+5.05%
|
-62.22
|
| Net Income Continuous Operations |
|
149.05
+886.25%
|
-18.96
+67.91%
|
-59.08
+5.05%
|
-62.22
|
| Normalized Income |
|
-5.79
+56.94%
|
-13.46
+76.30%
|
-56.77
+8.76%
|
-62.22
|
| Net Income Common Stockholders |
|
63.52
+439.10%
|
-18.73
+68.29%
|
-59.08
+5.05%
|
-62.22
|
| Otherunder Preferred Stock Dividend |
|
85.53
+38280.80%
|
-0.22
|
—
|
—
|
| Diluted EPS |
|
—
|
-0.34
+74.44%
|
-1.33
+42.17%
|
-2.30
|
| Basic EPS |
|
—
|
-0.34
+74.44%
|
-1.33
+42.17%
|
-2.30
|
| Basic Average Shares |
|
—
|
54.63
+22.64%
|
44.55
+64.47%
|
27.09
|
| Diluted Average Shares |
|
—
|
54.63
+22.64%
|
44.55
+64.47%
|
27.09
|
| Diluted NI Availto Com Stockholders |
|
63.52
+439.10%
|
-18.73
+68.29%
|
-59.08
+5.05%
|
-62.22
|
| Gain On Sale Of PPE |
|
3.50
|
0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
7.20
-28.76%
|
10.10
-61.36%
|
26.14
-40.64%
|
44.04
|
| Current Assets |
|
7.09
-29.06%
|
10.00
-53.76%
|
21.63
-43.87%
|
38.53
|
| Cash Cash Equivalents And Short Term Investments |
|
6.38
-23.09%
|
8.29
-54.60%
|
18.26
-42.22%
|
31.60
|
| Cash And Cash Equivalents |
|
6.38
-23.09%
|
8.29
-54.60%
|
18.26
+327.97%
|
4.27
|
| Other Short Term Investments |
|
—
|
—
|
0.00
-100.00%
|
27.33
|
| Receivables |
|
0.00
-100.00%
|
0.64
|
0.00
|
—
|
| Other Receivables |
|
—
|
0.64
|
—
|
—
|
| Prepaid Assets |
|
0.49
-38.36%
|
0.80
-71.11%
|
2.75
|
—
|
| Restricted Cash |
|
—
|
—
|
0.00
-100.00%
|
0.05
|
| Other Current Assets |
|
0.23
-18.44%
|
0.28
-54.52%
|
0.62
-91.00%
|
6.89
|
| Total Non Current Assets |
|
0.10
+1.00%
|
0.10
-97.78%
|
4.51
-17.98%
|
5.50
|
| Net PPE |
|
—
|
0.00
-100.00%
|
1.28
+166.74%
|
0.48
|
| Gross PPE |
|
—
|
0.00
-100.00%
|
1.74
-20.16%
|
2.18
|
| Accumulated Depreciation |
|
—
|
0.00
+100.00%
|
-0.46
+73.02%
|
-1.70
|
| Properties |
|
—
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
0.00
-100.00%
|
1.21
+2718.60%
|
0.04
|
| Machinery Furniture Equipment |
|
—
|
0.00
-100.00%
|
0.48
+2.76%
|
0.47
|
| Other Properties |
|
—
|
—
|
—
|
1.40
|
| Leases |
|
—
|
0.00
-100.00%
|
0.05
-82.96%
|
0.27
|
| Goodwill And Other Intangible Assets |
|
—
|
0.00
-100.00%
|
3.14
+0.00%
|
3.14
|
| Goodwill |
|
—
|
0.00
-100.00%
|
0.88
+0.00%
|
0.88
|
| Other Intangible Assets |
|
—
|
—
|
2.26
+0.00%
|
2.26
|
| Other Non Current Assets |
|
0.10
+1.00%
|
0.10
+11.11%
|
0.09
-95.22%
|
1.88
|
| Total Liabilities Net Minority Interest |
|
0.65
-99.58%
|
153.77
-2.26%
|
157.33
+2.68%
|
153.22
|
| Current Liabilities |
|
0.65
-61.28%
|
1.67
-66.39%
|
4.96
-62.95%
|
13.38
|
| Payables And Accrued Expenses |
|
0.62
-61.37%
|
1.62
-65.60%
|
4.70
-55.96%
|
10.68
|
| Payables |
|
0.27
-79.22%
|
1.27
-7.27%
|
1.38
-61.60%
|
3.58
|
| Accounts Payable |
|
0.27
-79.22%
|
1.27
-7.27%
|
1.38
-61.60%
|
3.58
|
| Current Accrued Expenses |
|
0.36
+4.96%
|
0.34
-89.69%
|
3.33
-53.12%
|
7.10
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.02
-58.33%
|
0.05
-60.33%
|
0.12
-95.44%
|
2.65
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
0.13
+202.27%
|
0.04
|
| Current Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.13
+202.27%
|
0.04
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
152.10
-0.17%
|
152.37
+8.96%
|
139.84
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
1.12
|
0.00
|
| Long Term Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
1.12
|
0.00
|
| Non Current Deferred Liabilities |
|
—
|
0.00
-100.00%
|
0.20
+0.00%
|
0.20
|
| Non Current Deferred Taxes Liabilities |
|
—
|
0.00
-100.00%
|
0.20
+0.00%
|
0.20
|
| Other Non Current Liabilities |
|
—
|
151.05
+0.00%
|
151.05
+8.17%
|
139.63
|
| Stockholders Equity |
|
6.55
+104.56%
|
-143.67
-9.52%
|
-131.19
-20.15%
|
-109.18
|
| Common Stock Equity |
|
3.97
+102.68%
|
-148.04
-12.85%
|
-131.19
-20.15%
|
-109.18
|
| Capital Stock |
|
2.65
-40.36%
|
4.45
+8135.19%
|
0.05
+92.86%
|
0.03
|
| Common Stock |
|
0.07
+0.00%
|
0.07
+38.89%
|
0.05
+92.86%
|
0.03
|
| Preferred Stock |
|
2.58
-41.06%
|
4.37
|
0.00
|
0.00
|
| Share Issued |
|
75.46
+0.00%
|
75.46
+38.74%
|
54.39
+90.78%
|
28.51
|
| Ordinary Shares Number |
|
75.46
+0.00%
|
75.46
+38.74%
|
54.39
+90.78%
|
28.51
|
| Additional Paid In Capital |
|
311.21
+0.96%
|
308.25
+0.68%
|
306.17
+13.76%
|
269.14
|
| Retained Earnings |
|
-307.31
+32.66%
|
-456.36
-4.33%
|
-437.41
-15.62%
|
-378.32
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
0.00
+100.00%
|
-0.02
|
| Other Equity Adjustments |
|
—
|
—
|
—
|
-0.02
|
| Total Equity Gross Minority Interest |
|
6.55
+104.56%
|
-143.67
-9.52%
|
-131.19
-20.15%
|
-109.18
|
| Total Capitalization |
|
6.55
+104.56%
|
-143.67
-9.52%
|
-131.19
-20.15%
|
-109.18
|
| Working Capital |
|
6.45
-22.62%
|
8.34
-50.01%
|
16.67
-33.73%
|
25.16
|
| Invested Capital |
|
3.97
+102.68%
|
-148.04
-12.85%
|
-131.19
-20.15%
|
-109.18
|
| Total Debt |
|
—
|
0.00
-100.00%
|
1.25
+2740.91%
|
0.04
|
| Capital Lease Obligations |
|
—
|
0.00
-100.00%
|
1.25
+2740.91%
|
0.04
|
| Net Tangible Assets |
|
6.55
+104.56%
|
-143.67
-6.96%
|
-134.32
-19.59%
|
-112.32
|
| Tangible Book Value |
|
3.97
+102.68%
|
-148.04
-10.21%
|
-134.32
-19.59%
|
-112.32
|
| Derivative Product Liabilities |
|
0.00
-100.00%
|
1.05
|
0.00
|
—
|
| Preferred Stock Equity |
|
2.58
-41.06%
|
4.37
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-6.05
+50.19%
|
-12.14
+72.92%
|
-44.85
-3.27%
|
-43.43
|
| Cash Flow From Continuing Operating Activities |
|
-6.05
+50.19%
|
-12.14
+72.92%
|
-44.85
-3.27%
|
-43.43
|
| Net Income From Continuing Operations |
|
149.05
+886.25%
|
-18.96
+67.91%
|
-59.08
+5.05%
|
-62.22
|
| Depreciation Amortization Depletion |
|
0.00
-100.00%
|
0.02
-92.28%
|
0.26
+127.19%
|
0.11
|
| Depreciation And Amortization |
|
0.00
-100.00%
|
0.02
-92.28%
|
0.26
+127.19%
|
0.11
|
| Other Non Cash Items |
|
—
|
3.84
-66.33%
|
11.41
-1.36%
|
11.57
|
| Stock Based Compensation |
|
0.41
-83.89%
|
2.54
-54.23%
|
5.56
-22.39%
|
7.16
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
3.14
|
0.00
|
—
|
| Deferred Tax |
|
0.00
+100.00%
|
-0.20
|
0.00
+100.00%
|
-0.07
|
| Deferred Income Tax |
|
0.00
+100.00%
|
-0.20
|
0.00
+100.00%
|
-0.07
|
| Operating Gains Losses |
|
-154.84
-38227.48%
|
-0.40
-461.11%
|
-0.07
|
—
|
| Gain Loss On Investment Securities |
|
-0.29
+34.96%
|
-0.45
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
-3.50
-7391.67%
|
0.05
+166.67%
|
-0.07
|
0.00
|
| Change In Working Capital |
|
-0.67
+68.75%
|
-2.13
+27.30%
|
-2.93
-17317.65%
|
0.02
|
| Change In Receivables |
|
—
|
0.00
-100.00%
|
3.24
+200.00%
|
-3.24
|
| Change In Prepaid Assets |
|
0.36
-84.44%
|
2.29
+346.50%
|
0.51
-79.68%
|
2.53
|
| Change In Payables And Accrued Expense |
|
-1.02
+77.18%
|
-4.47
+47.43%
|
-8.51
-1393.47%
|
0.66
|
| Change In Accrued Expense |
|
-0.01
+99.64%
|
-3.06
+51.50%
|
-6.30
-397.27%
|
2.12
|
| Change In Payable |
|
-1.01
+28.67%
|
-1.42
+35.81%
|
-2.21
-50.79%
|
-1.46
|
| Change In Account Payable |
|
-1.01
+28.67%
|
-1.42
+35.81%
|
-2.21
-50.79%
|
-1.46
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
-3.24
|
| Change In Other Current Assets |
|
-0.00
-101.12%
|
0.09
-95.39%
|
1.93
+485.45%
|
0.33
|
| Change In Other Current Liabilities |
|
0.00
+100.00%
|
-0.04
+63.46%
|
-0.10
+59.69%
|
-0.26
|
| Investing Cash Flow |
|
3.50
+7708.70%
|
-0.05
-100.17%
|
27.29
+13.75%
|
23.99
|
| Cash Flow From Continuing Investing Activities |
|
3.50
+7708.70%
|
-0.05
-100.17%
|
27.29
+13.75%
|
23.99
|
| Net PPE Purchase And Sale |
|
3.50
+87400.00%
|
0.00
+106.78%
|
-0.06
-136.00%
|
-0.03
|
| Purchase Of PPE |
|
—
|
0.00
+100.00%
|
-0.06
-136.00%
|
-0.03
|
| Sale Of PPE |
|
3.50
+87400.00%
|
0.00
|
0.00
|
—
|
| Capital Expenditure |
|
—
|
—
|
-0.06
-136.00%
|
-0.03
|
| Net Investment Purchase And Sale |
|
—
|
0.00
-100.00%
|
27.35
+13.88%
|
24.02
|
| Purchase Of Investment |
|
—
|
0.00
+100.00%
|
-22.64
+62.19%
|
-59.89
|
| Sale Of Investment |
|
—
|
0.00
-100.00%
|
49.99
-40.42%
|
83.91
|
| Net Business Purchase And Sale |
|
0.00
+100.00%
|
-0.05
|
0.00
|
—
|
| Purchase Of Business |
|
0.00
+100.00%
|
-0.05
|
0.00
|
—
|
| Financing Cash Flow |
|
0.64
-71.43%
|
2.22
-92.94%
|
31.50
+709.87%
|
3.89
|
| Cash Flow From Continuing Financing Activities |
|
0.64
-71.43%
|
2.22
-92.94%
|
31.50
+709.87%
|
3.89
|
| Net Common Stock Issuance |
|
0.64
-71.43%
|
2.22
-92.41%
|
29.30
+669.41%
|
3.81
|
| Proceeds From Stock Option Exercised |
|
—
|
0.00
-100.00%
|
2.20
+2612.35%
|
0.08
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
-1.91
+80.80%
|
-9.97
-171.50%
|
13.94
+189.69%
|
-15.54
|
| Beginning Cash Position |
|
8.29
-54.60%
|
18.26
+323.01%
|
4.32
-78.27%
|
19.86
|
| End Cash Position |
|
6.38
-23.09%
|
8.29
-54.60%
|
18.26
+323.01%
|
4.32
|
| Free Cash Flow |
|
-6.05
+50.19%
|
-12.14
+72.96%
|
-44.91
-3.35%
|
-43.45
|
| Common Stock Issuance |
|
0.64
-71.43%
|
2.22
-92.41%
|
29.30
+669.41%
|
3.81
|
| Issuance Of Capital Stock |
|
0.64
-71.43%
|
2.22
-92.41%
|
29.30
+669.41%
|
3.81
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-05-11 View
- 8-K2026-04-14 View
- 42026-04-09 View
- 42026-04-09 View
- 8-K2026-04-09 View
- 8-K2026-04-03 View
- 10-K2026-03-19 View
- 8-K2026-02-18 View
- 8-K2026-02-12 View
- 42025-11-24 View
- 10-Q2025-11-13 View
- 8-K2025-10-27 View
- 8-K2025-10-21 View
- 8-K2025-09-03 View
- 10-Q2025-08-13 View
- 10-Q2025-05-15 View
- 42025-05-05 View
- 42025-05-05 View
- 8-K2025-04-02 View
- 10-K2025-03-31 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|